Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer
Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Young mothers see rapid increase in substance-related emergency department visits
United Kingdom
-
Remission achievable with usual care for axial spondyloarthritis
United Kingdom
-
Heart drug combo reduces kidney damage in septic shock surgery, major trial finds
United Kingdom
-
Implantable device uses ultrasound to improve drug delivery to the brain
United Kingdom
-
Patient-reported outcomes worse for patients with rheumatoid arthritis discontinuing TNF inhibitor
United Kingdom
-
Next-generation drug reduces endometrial cancer progression and death in trial
United Kingdom
-
Trust and inclusive language key to effective vaccination campaigns, report finds
United Kingdom
-
Understanding the symptoms and treatments of pelvic organ prolapse
United Kingdom